- CME/CE Activities
- Renin-Angiotensin-Aldosterone System Therapies for Essential Hypertension
This CME/CE activity is provided by PRIME Education, Inc. (PRIME®) and is accredited for a multi-disciplinary audience of health care practitioners. This activity is supported by contract number HHSA290201200021I from the Agency for Healthcare Research and Quality. User data collected through this activity will reside on PRIME's educational portal for use by AHRQ.
Updates on the Comparative Effectiveness of Renin-Angiotensin-Aldosterone System Therapies for Essential Hypertension: A Feedback-Based Learning Activity
- Program Overview
- Faculty Biographies
- Accreditation Statements
- Post-Test & Evaluation
Credit for this CME/CE activity has expired.
You can still access the program, but will not receive a certificate.
Activity DescriptionTo systematically evaluate the comparative benefits and harms of ACE inhibitors and ARBs for patients with essential hypertension, the Agency for Healthcare Research and Quality (AHRQ) commissioned a comparative effectiveness review of published studies on these 2 therapy classes, which was published in 2007 and updated in 2011. In the updated 2011 review, evaluation of direct renin inhibitors was added. This video program explores the updated evidence, and provides individualized feedback-based learning by challenging learners with embedded questions that require keyboard responses. Health care professionals are challenged to think critically about optimal patient-centered therapies for managing hypertension. Hypertension affects approximately 75 million American adults and three-fourths of the population over 75 years of age, and is the primary attributable risk factor for death worldwide. Among the most common therapeutic options are agents that target the renin-angiotensin-aldosterone system (RAAS). These agents are grouped into 3 main classes: angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and direct renin inhibitors. Given marked differences in their mechanisms of action, one might expect that the RAAS-targeted therapies would vary in their efficacy and side-effect profiles.
At the conclusion of this activity, the participant should be able to:
- Compare the effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for controlling blood pressure and reducing risks of cardiovascular mortality and morbidity
- Assess key differences in side-effect profiles, tolerability, and persistence outcomes associated with ACE inhibitors, ARBs, and direct renin inhibitors
- Apply findings from the systematic review to guide decisions about appropriate patient-centered therapies for managing hypertension
This CME activity is designed to meet the educational needs of physicians, nurse practitioners, pharmacists, nurses, case managers, and health education specialists.
Method of Participation
To receive a certificate for this activity, you should:
- Complete the learner assessment pretest
- View the entire activity online
- Complete an online evaluation & post-test
- Print your certificate online
The estimated time to complete this activity, including review of the materials, is 1.0 hour.
Term of Approval
September 30, 2011 through September 30, 2013. Original release date: September 30, 2011.
Acknowledgement of Support
There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME®) and funded under contract HHSA290201200021I from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).
Faculty Biographies and Disclosures
Mori J Krantz, MD, FACC
Associate Professor of Cardiology
University of Colorado
Director, Cardiovascular Risk Reduction Program
Director, Cardiac Rehabilitation
Colorado Prevention Center
Carolyn LePage, PhD, ARNP
Barry University School of Nursing
Miami Shores, FL
Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
National Clinical Nursing Director
Department of Neurology
Multiple Sclerosis Center of Excellence, East
Veterans Affairs Medical Center
Trinity Nursing Program School of Professional Studies
Trinity Washington University
Clinical Preceptor and Instructor
Advanced Practice Programs
The Catholic University of America School of Nursing
Michele B Kaufman, PharmD, CGP, RPh
President, PRN Communications Inc.
Editor, Pharmacovigilance Forum, P&T Journal
Touro College of Pharmacy
New York, NY
Wanda F Carter, MPH, CHES
Adjunct Professor, Kaplan University Master of Public Health Program
Adjunct Professor, Axia College (U of Phoenix) Health Care Administration Program
Adjunct Professor, LA College International Health Care Administration Program
Adjunct Professor, Ashford University Health Care Administration Program
PHPS Alumnus, CDC Scientific Education and Professional Development Program Office
Debbie DeMuria, PharmD, RPh
Consultant, Regulatory Affairs
Joyce M Knestrick, PhD, CRNP, FAANP
Coordinator of Graduate Education
Frontier School of Midwifery and Family Nursing
Certified Family Nurse Practitioner
The Primary Care Center
Mt Morris, PA
Kathleen A Jarvis, MS, RN, CCM
Fort Lauderdale, FL
Sherman Podolsky, MD
Department of Emergency Medicine
Albert Einstein Medical Center
This program is no longer accredited.
|Faculty Name ||Advisory Board||Consultant||Grants / Research||Salary / Contractual||Supported Promotional Education||Stock / Shareholder||Other Financial Support|
|Mori J Krantz, MD, FACC
|None||None||GSK Lovaza Study||None||None||None||None|
|Carolyn LePage, PhD, ARNP
|Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
|Michele B Kaufman, PharmD, CGP, RPh
|Wanda F Carter, MPH, CHES
|Debbie DeMuria, PharmD, RPh
|None||Millennium Pharmaceuticals, Inc.||None||None||None||None||None|
|Joyce M Knestrick, PhD, CRNP, FAANP
|Kathleen A Jarvis, MS, RN, CCM
|Sherman Podolsky, MD
|Chris R Prostko, PhD|
Scientific Program Director
|Lynn Goldenberg, RN, BSN|
Director of Accreditation & Compliance
PRIME Education Inc (PRIME®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
PRIME® willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.
Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.
Content validation methods are consistently utilized by PRIME® to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME® complete disclosures which are related to their role in the educational activity.
PRIME®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.
To play the video below, your device must support HTML5 video (ex: iPad, Android, Chrome) or have Adobe Flash Player installed. Closed captioning is available by clicking the "CC" button in the top right of the video player.
Post-Test & Evaluation
Credit for this program has expired.
If you already completed this program and need to reprint your certificate(s), login here.
Clinician & Consumer Summaries on ACEIs and ARBs for Hypertension
Download these free summaries for your reference and/or patient handouts. You may also order bulk copies free of charge from the AHRQ Publication Clearinghouse below.